A former Netflix executive has filed a lawsuit claiming he was terminated after disclosing his medically prescribed ketamine use. The case highlights tensions between employee medical disclosures and workplace protection policies.

Key Takeaways

  • The executive alleges wrongful termination after revealing ketamine use.
  • He was dismissed from a $1.1 million salary position and is now suing the company.
  • The lawsuit raises questions about employer medical disclosure policies and labor law protections.

Incident Overview

A senior manager at Netflix, earning $1.1 million annually, disclosed during a company retreat’s “trust exercise” that he was taking medically prescribed ketamine. Shortly after, he was terminated, prompting legal action.

Legal Action

The executive has filed a complaint in a federal court in New York, alleging wrongful dismissal, breach of contract, and retaliation, seeking damages.

Netflix’s Response

Netflix has not issued a public comment yet, but the case is expected to test its HR policies regarding employee medical disclosures.

Why This Matters

BozokMedia analysis shows that such legal battles not only affect internal trust cultures but also reshape broader societal attitudes toward the use of mental‑health medications in the workplace.

"Balancing an employee’s right to medical disclosure with an employer’s safety concerns will define the next generation of employment law," says labor‑law expert Dr. Aria Patel.
Did You Know?: Ketamine received FDA approval in 2019 for treatment‑resistant depression, moving it beyond a simple “recreational drug” label.

Frequently Asked Questions

Q: On what legal grounds is the executive suing?
A: He claims wrongful termination, breach of contract, and retaliation.

Q: Could this case change Netflix’s HR policies?
A: A ruling in his favor may force companies to revise medical disclosure procedures.